Bristol-Myers Squibb Co. paid CEO Giovanni Caforio about $18.7 million in total remuneration in 2017, up from about $16.9 million in 2016.
Caforio received almost $1.6 million in base salary and received compensation of almost $3.9 million from ?non-equity incentive plan, or incentive awards, the company stated in an SEC filing.
That compares to about $1.5 million in base salary and almost $3.0 million in compensation from the non-equity incentive plan in 2016.
The New York-based pharmaceutical's CEO, who is also the company's board chairman, received $12.7 million from stock awards in comparison to $11.8 million in the year-ago period.
Caforio's market, or payout, value of unearned shares from outstanding equity awards at the end of fiscal 2017 stands at $7.4 million.
The ratio of Caforio's annual total compensation compared to Bristol-Myers' median employee's total annual compensation for fiscal year 2017 is 169 to 1, or about $18.7 million compared to $110,280, respectively.